Eli Lilly

Protein degrader
#Collaboration #Eli Lilly #Gate Bioscience #Protein degradation

Lilly and Gate agree $870m deal for molecular gate medicines

Eli Lilly and Gate Bioscience have expanded their collaboration to discover, develop, and commercialise molecular gate therapeutics.   The expanded collaboration adds one target, with the opportunity to add a second target, to the companies’ existing work.   The programmes leverage Gate’s Molecular Gate drug discovery engine… Read More

#Business & Investment #News

handshake
#Autoimmune disease #Eli Lilly #Immunology #Mergers and acquisitions

Merida acquisition strengthens Lilly’s immunology capabilities

Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases.  Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions.   The… Read More

#Business & Investment #News #Trending News

Weight loss tablets
#Eli Lilly #GLP-1 #MHRA #Obesity #Type 2 diabetes #Weight loss

UK first in Europe to authorise Lilly’s weight loss tablet orforglipron

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and… Read More

#News #Regulatory

Eli Lilly Gateway Labs in South San Francisco, California.
#Eli Lilly #GLP-1 #Market reporting #Norstella

New index reveals Eli Lilly as the top ranked company

Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies.  The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. Read More

#Business & Investment #News #Trending News

Retatrutide
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Phase III trials confirm benefits of Lilly’s triple agonist retatrutide

Eli Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist.   In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some… Read More

#News #Trending News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Eli Lilly #Immunology / Virology & Vaccines #Mergers and acquisitions

Lilly expansion aims to “prevent disease at its source”

Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million.  The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens… Read More

#Business & Investment #Editor's Choice #News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Lilly’s new triple agonist delivers weight loss equal to bariatric surgery

Eli Lilly has announced positive topline results from TRIUMPH-1, a Phase III clinical trial evaluating the efficacy and safety of retatrutide, a GIP, GLP-1,and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes.   At 80 weeks,… Read More

#News

#AI #Collaborative Drug Discovery (CDD) #Eli Lilly

CDD to make Eli Lilly models available in CDD Vault 

Collaborative Drug Discovery (CDD) has announced an agreement with Eli Lilly to make Lilly’s AI/ML models available in CDD Vault.  The models will come from Lilly TuneLab, the platform created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly’s… Read More

#News

Cholesterol test
#Cardiovascular disease #Cholesterol #Eli Lilly #Gene therapy

Single-shot gene therapy could cut cholesterol by 62% 

A single-shot gene therapy could slash cholesterol levels by 62%, potentially ‘transforming cardiovascular care’.  Results from the Heart-2 study into VERVE-102, published in The New England Journal of Medicine, showed reductions of up to 62% in a cohort of 35 participants, with durability observed for up… Read More

#News

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This,… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

CAR-T cell attacking cancer
#CAR-T #Cell therapy #Eli Lilly #Mergers and acquisitions

Lilly buys in vivo CAR-T developer Kelonia Therapeutics

Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion.  Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to… Read More

#Business & Investment #News